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Angiopoietin-2 predicts morbidity 
in adults with Fontan physiology
Aditya S. Shirali1,8, Gentian Lluri2,8*, Pierre J. Guihard3, Miles B. Conrad4, Helen Kim5,6, 
Ludmila Pawlikowska5,6, Kristina I. Boström3, M. Luisa Iruela-Arispe  7 & 
Jamil A. Aboulhosn2*
Morbidity in patients with single-ventricle Fontan circulation is common and includes arrhythmias, 
edema, and pulmonary arteriovenous malformations (PAVM) among others. We sought to identify 
biomarkers that may predict such complications. Twenty-five patients with Fontan physiology and 12 
control patients with atrial septal defects (ASD) that underwent cardiac catheterization were included. 
Plasma was collected from the hepatic vein and superior vena cava and underwent protein profiling 
for a panel of 20 analytes involved in angiogenesis and endothelial dysfunction. Ten (40%) of Fontan 
patients had evidence of PAVM, eighteen (72%) had a history of arrhythmia, and five (20%) were 
actively in arrhythmia or had a recent arrhythmia. Angiopoietin-2 (Ang-2) was higher in Fontan patients 
(8,875.4 ± 3,336.9 pg/mL) versus the ASD group (1,663.6 ± 587.3 pg/mL, p < 0.0001). Ang-2 was higher 
in Fontan patients with active or recent arrhythmia (11,396.0 ± 3,457.7 vs 8,118.2 ± 2,795.1 pg/mL, 
p < 0.05). A threshold of 8,500 pg/mL gives Ang-2 a negative predictive value of 100% and positive 
predictive value of 42% in diagnosing recent arrhythmia. Ang-2 is elevated among adults with Fontan 
physiology. Ang-2 level is associated with active or recent arrhythmia, but was not found to be 
associated with PAVM.
Patients with functional single ventricle require a staged surgical approach starting in the neonatal period and 
eventually culminating in total cavopulmonary connection or atriopulmonary connection (Fontan pallia-
tion) typically during early childhood. The Fontan procedure, which functionally separates the systemic and 
pulmonary circulations, alleviates chronic volume overload and cyanosis at the expense of a variety of chronic 
end-organ injuries1. Morbidity of the Fontan procedure is common and includes ventricular dysfunction, rhythm 
and conduction disturbances, hepatomegaly, ascites, peripheral edema, protein losing enteropathy, and pulmo-
nary arteriovenous malformations (PAVMs)2. While diagnosis of these complications is routine, early detection 
and prevention of these complications continues to challenge clinicians. The development of effective noninvasive 
strategies to detect and target these complications is essential for the treatment of this patient group. One such 
approach has been the identification of biomarkers to predict burden, prognosis, or potential response to a par-
ticular treatment of choice.
The use of biomarkers is increasingly being integrated into the management of adult congenital heart disease 
(CHD)3. As the number of Fontan patients reaching adulthood increases, a significant interest has emerged in 
utilizing biomarkers to predict Fontan failure and the development of PAVMs4–8. Elucidating the etiology of 
PAVMs in Fontan patients may pinpoint a potential noninvasive biomarker for the presence and severity of these 
malformations. Growing evidence suggests that the liver may play a role in the development of PAVMs. This 
is supported by the findings that the PAVMs are found in the lung or lungs that do not receive hepatic venous 
effluent, and redirection of hepatic blood flow to the pulmonary arteries leads to resolution of the PAVMs9–11. 
While several theories implicate the presence of an anti-angiogenic factor in hepatic venous effluent, no study has 
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specifically examined the plasma protein profile of the hepatic vein in patients with PAVM to identify a putative 
factor responsible for PAVM development12,13.
In this study, we examined the molecular profile of the hepatic vein in Fontan patients with and without 
PAVMs to identify potential factors involved in arteriovenous malformation development. Furthermore, we used 
a similar approach to identify profile differences between Fontan patients and non-Fontan patients and proteins 
involved in the detection of Fontan morbidity.
Results
Patient characteristics. Clinical characteristics of patients with Fontan circulation (n = 25) and with atrial 
septal defects (ASD, n = 12) included in this study are shown in Table 1. Among adult congenital heart disease 
patients who undergo comprehensive diagnostic or interventional cardiac catheterization, patients with atrial 
septal defects are considered to have a simple congenital defect and most closely resemble patients with biven-
tricular function. There was no statistical difference between the age of the Fontan group (32.2 ± 9.1 years) and 
the age of the ASD group (28.6 ± 10.6 years, p = 0.29). Forty percent of the Fontan group were females and 25% 
of the ASD group were males. Among the Fontan group the initial diagnoses included: 20% with dextro-trans-
position of great vessels (d-TGA), 20% with double outlet right ventricle, 16% with double inlet left ventricle, 
16% with tricuspid atresia, and 28% labeled as ‘other,’ including hypoplastic left heart syndrome, unbalanced AV 
canal, and pulmonary atresia. Current Fontan types included lateral tunnel (52%), extracardiac (32%), and atrio-
pulmonary (16%). Among these patients, 6 patients (3 extracardiac and 3 lateral tunnel) had a history of Fontan 
fenestration, among which 5 patients had the fenestration closed more than 8 years prior to study inclusion, and 
one patient with residual small fenestration at the time of cardiac catheterization. The average Fontan pressure 
during cardiac catheterization was 15.3 ± 5.0 mmHg.
Forty percent of Fontan patients had evidence of PAVM at the time of plasma collection, while no ASD 
patients had PAVMs. One Fontan patient had a history of protein-losing enteropathy and 32% of Fontan patients 
had clinical evidence of ascites. Of the twenty five Fontan patients, twelve underwent liver biopsy which demon-
strated normal tissue in two patients, fibrosis in six patients, and cirrhosis in four patients. Seventy-two percent 
of the Fontan patients had a history of arrhythmia, while none of patients in the ASD group had a history of 
Fontan 
(n = 25)
Atrial Septal Defect 
(n = 12)
Age, y 32.2 ± 9.1 28.6 ± 10.6
Male, n (%) 10 (40) 3 (25)
Diagnosis, n (%)
Atrial Septal Defect 0 (0) 12 (100)
d-TGA 5 (20) 0
Double Outlet RV 5 (20) 0
Double Inlet LV 4 (16) 0
Tricuspid Atresia 4 (16) 0
Other 7 (28) 0
Fontan Type, n (%)
Lateral Tunnel 13 (52) —
Extracardiac 8 (32) —
Atriopulmonary 4 (16) —
Central Venous Pressure, mmHg 15.3 ± 4.9 7.6 ± 3.2
Fontan Pressure, mmHg 15.3 ± 5.0 —
Presence of AVM n (%) 10 (40) 0
History of PLE, n (%) 1 (4) 0
Clinical Ascites, n (%) 8 (32) 0
Liver Biopsy n (%)
Normal 2 (8) —
Fibrosis 6 (24) —
Cirrhosis 4 (16) —
Not Performed 13 (52) 12
Arrhythmia within 6 months, n (%) 5 (20) 0
History of Arrhythmia, n (%) 18 (72) 0
Atrial Flutter 10 (56) —
Atrial Tachycardia 5 (28) —
Other 2 (16) —
Table 1. Baseline Demographic and Clinical Data of Study Group. d-TGA, dextro-Transposition of Great 
Vessels; LV, Left Ventricle; RV, Right Ventricle; AVM, arteriovenous malformation; PLE, Protein-Losing 
Enteropathy.
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arrhythmia. Among the Fontan group, five patients (20%) were either in active arrhythmia or had a history of 
arrhythmia within 6 months of plasma collection.
Plasma analysis in Fontan patients. To identify a putative hepatic factor involved in PAVM develop-
ment, blood was collected from the hepatic vein and superior vena cava and plasma protein levels from both loca-
tions were compared. We performed a Luminex Assay of plasma obtained from both locations in Fontan patients 
with AVM (n = 4), Fontan patients without AVM (n = 2), and ASD patients without PAVM (n = 6) to probe for 20 
plasma proteins involved in angiogenesis and endothelial dysfunction and the difference in levels between the two 
locations was calculated for those with PAVM and those without PAVM. Results are summarized in Table 2. No 
statistically significant differences were found in any of the 20 plasma proteins assays when comparing those with 
and without PAVM, suggesting that the hepatic and systemic venous circulations are similar in regards to these 
specific plasma proteins. For this particular analysis, the number of Fontan patients is too small to separately 
analyze the different types of Fontan patients
However, when comparing those with Fontan physiology (n = 6) to those with ASD (n = 6), differences that 
were statistically significant, as defined as p ≤ 0.0025 to account for multiple comparisons with the Bonferonni 
correction, were observed in Ang-2 (Table 2). Angiopoietin-2, a protein involved in the regulation of permea-
bility, angiogenesis, and inflammation, was found to be 6-fold higher in patients with Fontan physiology than in 
ASD patients (p < 0.001)14. Further analysis of Ang-2 levels in the remaining cohort of patients showed a persis-
tent elevation in Fontan patients when compared to ASD patients (Fig. 1).
Fontan patients had Ang-2 levels of 8,875.4 ± 3,336.9 pg/mL compared to ASD patients with 
1,663.6 ± 587.3 pg/mL, a 5.3-fold difference (p < 0.0001). As seen in the Luminex Assay, Ang-2 has no correlation 
with PAVM formation and was confirmed in the entire cohort of Fontan patients. Angiopoietin-2 levels were 
8,342.7 ± 3,780.1 pg/mL in Fontan patients with PAVM (n = 10) and 9,230.5 ± 3,092.8 pg/mL in those without 
PAVM (n = 15), demonstrating no statistical difference (p = 0.53, Fig. 2A). Furthermore, when comparing Ang-2 
levels in Fontan patients to patients with hereditary hemorrhagic telangiectasia (HHT) and confirmed PAVMs, 
Ang-2 was found to be 4.2-fold higher in Fontan patients (8,875.4 ± 3,336.9 pg/mL) than in HHT patients with 
PAVMs (2,227.1 ± 968.5 pg/mL) as seen in Fig. 2B.
Clinical outcomes. Given the absence of Ang-2 elevation in HHT patients with PAVM and the consist-
ent elevation in all Fontan patients regardless of the presence of AVM, the elevation of this protein in Fontan 
patients likely serves as a marker of endothelial and cardiac dysfunction rather than an angiogenic marker. 
There was no statistically significant correlation between Ang-2 level and Fontan pressure measured during car-
diac catheterization (r = 0.1599, p = 0.54). Fontan patients with clinical evidence of ascites had average Ang-2 
levels of 10,339.6 ± 3,558.2 pg/mL versus those without ascites who had average levels of 8,186.3 ± 3,096.7 pg/
mL (p = 0.14, Supplementary Figure 1A). In addition, no association between Ang-2 levels and degree of liver 
fibrosis or cirrhosis on liver biopsy was found (p = 0.14). The average Ang-2 levels in those with cirrhosis was 
Analyte (pg/mL) Fontan (n = 6) ASD (n = 6) P-Value
Ang-2 7,710.3 ± 2,490.9 1,279.0 ± 637.8 0.000514447*
BMP9 454.0 ± 286.8 359.8 ± 348.6 0.653182
CD44 3,538.7 ± 2317.8 4,006.8 ± 2,614.8 0.772179
E-Selectin 34,278.2 ± 18,351.3 27,824.4 ± 13,118.6 0.54023
EGF 167.5 ± 182.6 129.3 ± 105.2 0.69593
Endostatin 37,581.1 ± 22,718.2 23,190.8 ± 7,085.4 0.213307
FABP4 22,240.5 ± 10,520.7 7,084.5 ± 3,491.6 0.0156468
FGF23 40.8 ± 30.6 11.2 ± 15.5 0.0899409
Gas6 12,481.9 ± 1,928.5 10,038.0 ± 1,721.7 0.0674726
ICAM1 364,736.7 ± 324,691.3 310,227.1 ± 229,749.8 0.767095
MCP-1 114.6 ± 27.3 94.6 ± 26.8 0.276038
MMP1 181.3 ± 99.3 120.9 ± 89.4 0.341724
MMP13 2,093.4 ± 1,229.5 1,863.5 ± 1,462.3 0.794634
MMP3 4,197.9 ± 1,867.9 3,398.9 ± 937.7 0.417549
MMP7 4,874.0 ± 3,775.1 1,212.2 ± 698.6 0.065511
MMP9 11,518.6 ± 2,993.2 10,956.7 ± 2,116.4 0.740628
Tenascin C 9,419.2 ± 1,739.3 7,548.6 ± 1,848.7 0.137993
TIMP1 60,061.3 ± 14,914.8 35,175.4 ± 4,833.5 0.0157517
Thrombospondin-2 59,903.9 ± 20,234.4 19,256.1 ± 16,455.9 0.00825944
vWF 3,418.5 ± 2,896.7 3,220.0 ± 1,781.3 0.899399
Table 2. Differences in analyte concentrations (pg/mL) between Fontan and ASD patients. Ang-2, 
angiopoietin-2; BMP9, bone morphogenic protein 9; EGF, epidermal growth factor; FABP4, fatty acid binding 
protein 4; FGF23, fibroblast growth factor 23; Gas6, growth arrest-specfic protein 6; ICAM1, intracellular 
adhesion molecule 1; MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; TIMP1, 
tissue inhibitor of metalloproteinase 1; vWF, von Willebrand factor.
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5,863 ± 797.7 pg/mL (n = 4) versus 8,475.5 ± 3,150.2 pg/mL (n = 6, p = 0.15) in those with fibrosis. Interestingly, 
Fontan patients with history of arrhythmia had average Ang-2 levels of 9,692.5 ± 3,379.2 pg/mL compared to 
those with no arrhythmia history with levels of 6,374.7 ± 1,651.0 pg/mL which trended toward statistical sig-
nificance (p = 0.07). Those with active arrhythmia (defined as a clinically symptomatic arrhythmia that necessi-
tated intervention by either medication adjustment or electrophysiology study/ablation) or arrhythmia within 6 
months (20% of patients) had an average Ang-2 level of 11,396.0 ± 3,457.7 pg/mL versus those without a recent 
history with levels of 8,118.2 ± 2,795.1 pg/mL (p < 0.05). Forty-two percent of patients with levels above 8,500 pg/
mL were in active arrhythmia or had a recent arrhythmia, while no patients with values less than 8,500 pg/
mL were in active arrhythmia or had recent history of arrhythmia (p < 0.05, Supplementary Figure 1B). Using 
8,500 pg/mL as a cutoff threshold, Ang-2 has a negative predictive value of 100% and suggests plasma Ang-2 levels 
may be used to screen for those Fontan patients at risk for development of an arrhythmia.
Discussion
The present study tests the hypothesis that differences in plasma protein profiles exist between the hepatic vein 
and systemic venous circulation and that these differences account for the development of PAVM in Fontan 
patients. Multiple studies have demonstrated the formation of PAVMs whenever hepatic venous effluent does not 
perfuse the pulmonary arteries directly, either congenitally or postoperatively10,15, suggesting the presence of an 
Figure 1. Plasma angiopoietin-2 levels in in Fontan patients (red triangle, n = 25) and ASD patients (green 
circle, n = 12). Angiopoietin-2 levels are significantly higher in Fontan patients (p < 0.0001). Lines represent 
mean ± standard deviation.
Figure 2. (A). Plasma angiopoietin-2 levels in in Fontan patients with AVM (red triangle, n = 10) and without 
AVM (green triangle, n = 15). There is no significant difference in angiopoietin-2 levels in Fontan patients with 
and without AVMs (p = 0.53) (B). Plasma angiopoietin-2 levels in in Fontan patients (red triangle, n = 25) 
and HHT patients (blue square, n = 23). Angiopoietin-2 levels are significantly higher in Fontan patients 
(p < 0.0001). Lines represent mean ± standard deviation.
5Scientific RepoRtS |         (2019) 9:18328  | https://doi.org/10.1038/s41598-019-54776-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
anti-angiogenic factor in the hepatic effluent that when absent induces vascular proliferation and angiogenesis 
in the pulmonary bed12. To test this hypothesis, we examined the difference in concentrations of plasma proteins 
involved in inhibiting angiogenesis and endothelial dysfunction in the hepatic vein and superior vena cava in 
those with and without PAVMs. No differences were seen in anti-angiogenic proteins BMP9, Endostatin, Gas6, 
Thrombospondin-2, or TIMP1. Furthermore, no differences were seen in any of the 20 plasma proteins queried, 
suggesting similar protein profiles between the hepatic vein and the systemic venous circulation.
However, comparing the venous plasma proteins of Fontan patients with ASD patients shows demonstra-
ble differences in several proteins involved in angiogenesis, Ang-2, FABP4, TIMP1, and Thrombospondin-2, 
with only Ang-2 meeting the criteria for statistical significance and the other three proteins approaching signif-
icance. Thrombospondin-2 and TIMP1 are both glycoproteins involved in inhibiting degradation of cell-matrix 
interactions and extracellular matrix, and have shown potent anti-angiogenic activities16,17. Elevations in these 
proteins in Fontan patients may reflect a systemic compensatory mechanism to the excessive pulmonary angio-
genesis involved in PAVM formation. FABP4, a protein involved in VEGF-mediated endothelial cell proliferation 
and implicated in the development of cerebral cavernous malformations, was found to be 2.5–3 fold higher in 
Fontan patients compared to ASD patients18. However, on further analysis, no differences in FABP4 were detected 
between those with clinically evident PAVMs and those without PAVMs (data not shown). Angiopoietin-2 was 
the only plasma protein queried in the Luminex Analysis that was statistically significantly higher in Fontan 
patients than ASD patients, which was further validated with the entire cohort of patients enrolled.
Ang-2 is an endothelial cell specific protein that is rapidly released in response to various stimuli, includ-
ing inflammatory cytokines, activated leukocytes, and hypoxia19,20. Release of Ang-2 induces loss of junctional 
integrity and inhibits endothelial cell quiescence, enhancing vascular permeability, inflammation and vascular 
remodeling14,21. It is especially pertinent that this protein is so elevated in Fontan patients who often exhibit exces-
sive vascular permeability including presence of ascites, pleural effusions and protein losing enteropathy. In this 
regard, it is possible to speculate that the dysfunction in endothelial barrier is a consequence of excessive Ang-2. 
Nevertheless, we found no relationship between Ang-2 and PAVM formation both in Fontan patients and HHT 
patients, suggesting the role Ang-2 plays in Fontan physiology is likely unrelated to PAVM formation.
Apart from its involvement in tumor-specific angiogenesis, Ang-2’s role in inducing vascular permeability has 
led to evaluation of its role in critical illness, sepsis, volume overload, and cardiogenic shock22–25. Studies in crit-
ical care medicine have demonstrated that patients in septic shock exhibit remarkable levels of endothelial acti-
vation with release of Ang-2 resulting in acute lung injury, hepatic dysfunction, coagulopathy, and acute kidney 
injury22,26. In fact, these studies have identified a threshold of 5,900 pg/mL as being associated with higher mor-
tality26,27. Furthermore, Ang-2 levels greater than 2,500 pg/mL were independent predictors of 28-day and 1-year 
mortality in patients with cardiogenic shock28. Interestingly, the Ang-2 levels in the Fontan patients included in 
this study were on average 4-fold higher than the levels predictive of increased mortality following cardiogenic 
shock and 1.5-fold higher than the levels associated with increased mortality in sepsis, highlighting the precarious 
long-term condition of Fontan patients and the need for close follow-up.
Yet, while all Fontan patients examined had Ang-2 levels greater than 2,500 pg/mL, and most had levels greater 
than 5,900 pg/mL, many of these patients had good functional capacity and led active lifestyles. Therefore, we 
examined whether the subgroup of Fontan patients with elevated Ang-2 levels may have more potent endothe-
lial dysfunction and whether Ang-2 levels may be associated with and potentially predict complications related 
to Fontan failure, particularly ascites or arrhythmias. Although we did not observe an elevation in Ang-2 lev-
els in those with ascites, we observed that patients with a history of arrhythmia had elevated Ang-2 levels that 
approached statistical significance. Studies have demonstrated that patients in chronic atrial fibrillation have 
elevated levels of plasma Ang-229,30. As such, we performed subgroup analysis of the cohort of patients with an 
arrhythmia history and found that patients who were in active arrhythmia at the time of plasma collection or had 
a sustained arrhythmia within the previous 6 months had statistically higher levels of Ang-2 levels than those 
without recent arrhythmia. Furthermore, using 8,500 pg/mL as a threshold, we found that Ang-2 has a negative 
predictive value of 100% and a positive predictive value of 42% of active or recent arrhythmia. The fairly low 
positive predictive value is not unexpected, given Ang-2’s association with sepsis, cardiogenic shock, and angio-
genesis14,26,28. However, the fact that no patients with levels less than 8,500 pg/mL had recent arrhythmias may be 
informative and may portend a more favorable prognosis in this population.
This study examines the association between a cohort of plasma proteins involved in angiogenesis and 
endothelial dysfunction with complications in Fontan patients, particularly PAVMs and arrhythmias. In the pro-
cess, we identified Ang-2 as a potential indicator of disease burden, particularly in association with arrhythmias. 
However, this study is not without its limitations. We attempted to identify biomarkers related to PAVM forma-
tion in Fontan patients based on the theory of a putative hepatic factor that was first posited in patients with a 
superior cavopulmonary connection (SCPC), in which one or both lungs are devoid of hepatic vein effluent. Yet, 
significant regression of PAVMs has been noted after redistribution of flow with Fontan completion. Of note, 
we circumvented this redistribution of plasma proteins after Fontan completion by selectively obtaining plasma 
directly from the hepatic vein and performing multiplex analysis on a panel of proteins involved in angiogenesis 
and endothelial dysfunction. We found no significant differences between the panel of proteins in those without 
and without PAVMs. This outcome may be due to the biased selection of proteins in our panel or the existence of 
an undetectable or unselected protein; or it may indicate different etiological factors involved in PAVM formation 
in Fontan patients with no separation of hepatic and systemic venous circulation versus those with SCPC. The 
coincidental finding of Ang-2 elevation in Fontan patients and its association with critical illness is both com-
pelling and concerning given the strong statistical difference found between Fontan patients in comparison to 
both ASD and HHT patients and the marked elevation in comparison to values that predict increased mortality. 
Nonetheless, longitudinal studies are necessary to fully validate the robustness of Ang-2 as a prognostic indicator 
of arrhythmia. Another limitation is that, for the control group our study does not include patients with other 
6Scientific RepoRtS |         (2019) 9:18328  | https://doi.org/10.1038/s41598-019-54776-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
cardiovascular conditions that have elevated inferior vena cava pressures like RV dysfunction or severe tricuspid 
valve regurgitation.
In conclusion, we found no differences in hepatic plasma protein profile between those with and without 
PAVM. Plasma Ang-2 levels, however, were found to be significantly elevated in all Fontan patients. Ang-2 eleva-
tion was not found to predict PAVM formation, but we identified an association with active or recent arrhythmia. 
We believe our results warrant future longitudinal investigation to fully elucidate the prognostic potential of this 
endothelial activator.
Methods
Study sample, sample collection, and clinical assessment. Patients aged ≥18 years treated at the 
Ahmanson/UCLA Adult Congenital Heart Disease Center who had previously undergone a Fontan procedure 
and who also underwent routine cardiac catheterization between March 2016 and April 2017 at Ronald Reagan 
UCLA Medical Center were prospectively consented for study inclusion. Age- and sex-matched patients with 
atrial septal defects (ASDs) undergoing cardiac catheterization, selected based on the distribution of Fontan par-
ticipants by sex and 10-year age group rather than matched to individual participants, were identified. The study 
was approved by the University of California, Los Angeles institutional review board (IRB) and informed consent 
was obtained prior to enrollment from all participants. All methods were performed in accordance with relevant 
guidelines and regulations.
Fontan patients underwent cardiac catheterization for assessment of Fontan hemodynamics and/or electro-
physiology study if clinically indicated, while ASD patients underwent catheterization for percutaneous defect 
closure. During cardiac catheterization, blood was collected from the hepatic vein and superior vena cava. 
Presence of arteriovenous malformation (AVM) was determined by detection of five or more bubbles in the left 
atrium after injection of agitated saline into the distal right and left pulmonary arteries during transesophageal 
echocardiography.
Medical records were retrospectively reviewed for patient demographic information and clinical character-
istics. Clinical information was collected pertaining to pre-Fontan diagnosis, Fontan type, presence of AVM, 
and Fontan-related clinical outcomes, including ascites, protein-losing enteropathy, liver cirrhosis/fibrosis and 
arrhythmia. From a prior IRB-approved study of AVM patients at University of California, San Francisco, fif-
teen venous plasma samples were obtained from patients with a diagnosis of hereditary hemorrhagic telangi-
ectasia (HHT) by Curaçao criteria and PAVM screening and confirmation according to the International HHT 
Guidelines31.
Biomarker assessment. Blood collected via cardiac catheterization was processed to plasma within 30 min-
utes to an hour of collection and frozen at −80 °C. A Luminex Screening Assay (R&D Systems Inc., Minneapolis, 
MN), a polystyrene bead-based multi-analyte profiling platform, was performed for twenty analytes involved 
in angiogenesis and endothelial dysfunction. This assay was performed on plasma samples from the hepatic 
vein and superior vena cava from twelve patients (six Fontan patients and six ASD patients). Angiopoietin-2 
(Ang-2) concentration was measured with an enzyme-linked immunoassay on all plasma samples (R&D Systems 
Inc, Minneapolis, MN). The assessed inter-assay precision of the kit used demonstrated a coefficient of varia-
tion between 7.4 and 10.4%. Intra-assay precision demonstrated a coefficient of variation between 4.2 and 6.9%. 
Measurements were performed in duplicate at 1:5 dilutions. Measurement variability was minimal and compara-
ble with that reported in the kit.
Statistical analysis. Frequencies were tabulated for categorical variables. The two-sided unpaired Student 
t test was used to compare continuous variables. ANOVA was performed to evaluate differences in continuous 
variables between three or more groups. For comparison of analyte levels identified in the Luminex Assay, a 
Bonferonni correction for multiple comparison was used when determining the level of statistical significance, 
setting a p-value limit of 0.0025 for statistical significance. The Fisher exact test was used to analyze categorical 
variables between groups stratified by Ang-2 level with a p-value for statistical significance set at less than 0.05. A 
Pearson correlation was performed between Ang-2 level and continuous variables of interest. All analyses were 
performed using GraphPad Prism 6 (La Jolla, CA).
Ethics approval. University of California Los Angeles IRB. University of California San Francisco IRB.
Received: 28 January 2019; Accepted: 14 November 2019;
Published: xx xx xxxx
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